Oligonucleotide & ASO CDMOs — Ranked by Signal Score · 2026

Last updated: 2026-09-23 · updated as new inspection, certificate, and trial data enters the platform

Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

Shortlist oligonucleotide CDMOs with Signal

CDMO Signal is an independent sourcing platform ASO, siRNA, and aptamer sponsors use to compare and shortlist oligonucleotide CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then verify chemistry, conjugation, scale, and analytical requirements directly with the shortlisted suppliers.

Compare oligonucleotide CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your ASO, siRNA, or aptamer program's shortlisting criteria.
Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to verify chemistry, conjugation, scale, and analytical requirements directly.

Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.

Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 8 NAI (no action), 10 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (16), Spain (10), Italy (9), Germany (5), Belgium (4).

Last updated 2026-09-23. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	AL Agilent Technologies (Oligo GMP) Santa Clara, CA	74.2	100.0	2 insp · 0 GMP	—	1 programs
2	AX Axolabs (Nuvisan) Kulmbach, Germany	72.6	99.0	1 insp · 0 GMP	—	3 programs
3	AJ Ajinomoto Bio-Pharma Services San Diego, CA · Osaka, JP	83.5	100.0	0 insp · 1 GMP	—	0 programs
4	CD Corden Pharma Plankstadt, DE · Caponago, IT · Boulder, CO	81.1	98.9	4 insp · 10 GMP	—	0 programs
5	ND Nitto Denko Avecia Milford, MA	80.3	100.0	3 insp · 0 GMP	—	0 programs
6	KE Kaneka Eurogentec Seraing, BE	80.3	100.0	0 insp · 4 GMP	—	0 programs
7	BA Bachem Bubendorf, CH	80.0	95.4	3 insp · 0 GMP	—	0 programs
8	CRA Curia (RNA/Advanced) Albany, NY · Albuquerque, NM	79.4	99.9	2 insp · 18 GMP	—	0 programs
9	SP ST Pharm Seoul, South Korea	73.2	89.4	2 insp · 4 GMP	—	0 programs
10	TL TriLink BioTechnologies San Diego, CA	71.0	—	—	—	0 programs
11	PP PolyPeptide Group Torrance, CA · Strasbourg, FR · Malmo, SE	66.1	74.2	3 insp · 0 GMP	—	0 programs
12	LG LGC Biosearch Technologies Petaluma, CA · Middleton, WI	63.0	—	—	—	0 programs
13	SM Sumitomo Chemical Advanced Medical Tokyo, JP	63.0	—	—	—	0 programs
14	AU Aurigene Pharmaceutical Services Hyderabad, India	63.0	—	—	—	0 programs
15	RR RiboBio Guangzhou, China	59.0	—	—	—	0 programs
16	HB Hongene Biotech Singapore (primary operations: Union City, CA / Shanghai, China)	56.5	—	—	—	0 programs
17	BS Bio-Synthesis Inc. Lewisville, TX	56.5	—	—	—	0 programs
18	CG2 ChemGenes Corporation Wilmington, MA	56.5	—	—	—	0 programs
19	MM Mermade (BioAutomation) Irving, TX	56.5	—	—	—	0 programs
20	GR Glen Research Sterling, VA	56.5	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Oligonucleotide / ASO CDMO

Synthesis scale

Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.

Chemistry & conjugation

Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.

Purity & analytics

Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Oligonucleotide / ASO CDMOs — Frequently Asked Questions

Who are the top Oligonucleotide / ASO CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Oligonucleotide / ASO CDMOs include Agilent Technologies (Oligo GMP), Axolabs (Nuvisan), Ajinomoto Bio-Pharma Services. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Oligonucleotide / ASO CDMOs have FDA inspection records?

CDMO Signal tracks 8 Oligonucleotide / ASO CDMOs with FDA inspection records and 37 EMA/MHRA GMP certificates across the group.

What should I look for in an oligonucleotide CDMO?

Match synthesis scale to your demand, confirm experience with your backbone chemistry and any conjugation (e.g. GalNAc), prioritize strong purity analytics, and a clean FDA and EMA/MHRA record.

What therapeutics do oligonucleotide CDMOs make?

Antisense oligonucleotides (ASOs), siRNAs, aptamers, and related nucleic-acid drugs — increasingly with conjugation chemistries like GalNAc for targeted delivery.

Related modalities

Plasmid DNA CDMOs mRNA / LNP CDMOs Biologics / mAb CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector